Literature DB >> 10567892

Results and 10-year follow-up in patients with squamous cell carcinoma of the penis.

P Derakhshani1, S Neubauer, M Braun, H Bargmann, A Heidenreich, U Engelmann.   

Abstract

Penile malignancies are infrequent but represent a diagnostic and therapeutic challenge as patients tend to disregard early asymptomatic lesions of the disease. Due to the lack of studies involving large patient numbers, the therapeutic concepts for different stages of the disease could not be defined by prospective studies. Long-term results are rare. We present the therapeutic concepts and the 10-year results of our experience with 42 cases of penile carcinoma treated at our institution between 1973 and 1986. Therapy included radical circumcision in 10 cases, local excision of the tumor in 4, partial or total glandular resection in 6 patients, partial penectomy in 20, and total penectomy in 2 cases. Inguinal lymphadenectomy was performed initially in 14 cases with positive histology in 7 patients (50%). Complications included meatal stenosis in 8 cases (19%), urethral stricture in 1 case, death due to fulminant pulmonary embolism in 1 case and local infections in 2 cases. Follow-up of patients with initially nonmetastatic disease showed a progression to death in 4 of 35 patients (11.6%) with a mean survival of 30 (range 11.5-56) months, in patients with initial lymph node metastases progression to death occurred in 5 of 7 patients (71.4%) with a mean survival of 9.76 months (range 9 days to 24 months). Stage-related disease-specific 10-year survival rates are 100% for stages 0 and 1, 90.9% for stage 2, and 20% for stage 3, while no patient in stage 4 survived for 5 years. From our data we conclude that the single most important prognostic factor in the treatment of carcinoma of the penis is lymph node involvement. Therefore increased attention has to be paid to the recognition of early stages of this potentially curable disease. Copyright 1999 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  1999        PMID: 10567892     DOI: 10.1159/000030405

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  7 in total

Review 1.  Non-invasive and minimally invasive staging of regional lymph nodes in penile cancer.

Authors:  Ben Hughes; Joost Leijte; Majid Shabbir; Nick Watkin; Simon Horenblas
Journal:  World J Urol       Date:  2008-07-02       Impact factor: 4.226

Review 2.  Current trends in the management of carcinoma penis--a review.

Authors:  Iqbal Singh; A Khaitan
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

Review 3.  [Value of targeted therapy for penile cancer].

Authors:  A Heidenreich; D Thüer; D Pfister
Journal:  Urologe A       Date:  2008-10       Impact factor: 0.639

4.  Imaging in primary penile cancer: current status and future directions.

Authors:  Rohit Kochhar; Ben Taylor; Vijay Sangar
Journal:  Eur Radiol       Date:  2009-08-06       Impact factor: 5.315

5.  [Neoadjuvant and adjuvant chemotherapy in patients with advanced penile cancer].

Authors:  A Heidenreich; G Jakse
Journal:  Urologe A       Date:  2007-10       Impact factor: 0.639

6.  Management of penile cancer patients during the COVID-19 pandemic: An eUROGEN accelerated Delphi consensus study.

Authors:  Omer Onur Cakir; Fabio Castiglione; Zafer Tandogdu; Justin Collins; Hussain M Alnajjar; Clare Akers; Maarten Albersen; Constantine Alifrangis; Benjamin Ayres; Oscar Brouwer; Ivor Cullen; Peter Hawkey; Jakob Kristian Jakobsen; Truls Erik Bjerklund Johansen; Odunayo Kalejaiye; Asheesh Kaul; Bela Köves; Vivekanandan Kumar; Mariangela Mancini; Anita Vanessa Mitra; Arie Parnham; Edoardo Pozzi; Chris Protzel; Vijay K Sangar; Florian Wagenlehner; Asif Muneer
Journal:  Urol Oncol       Date:  2021-01-01       Impact factor: 3.498

Review 7.  Detection of lymph node metastases in penile cancer.

Authors:  Jonathan B Bloom; Michael Stern; Neel H Patel; Michael Zhang; John L Phillips
Journal:  Transl Androl Urol       Date:  2018-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.